75
Participants
Start Date
October 7, 2020
Primary Completion Date
September 30, 2023
Study Completion Date
October 31, 2024
Axitinib Oral Tablet
"Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect."
Avelumab
Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
ACTIVE_NOT_RECRUITING
Azienda Ospedaliera Universitaria di Cagliari- P.O. Duilio Casula Monserrato, Monserrato
NOT_YET_RECRUITING
ASL CN2 Alba-Bra, Alba
NOT_YET_RECRUITING
Irccs Oncologico Istituto Tumori Giovanni Paolo Ii, Bari
NOT_YET_RECRUITING
ASST Papa Giovanni XXIII, Bergamo
NOT_YET_RECRUITING
Azienda Ospedaliero-Universitaria Di Bologna Suor Orsola Malpighi, Bologna
NOT_YET_RECRUITING
Ospedale Policlinico San Martino, Genova
NOT_YET_RECRUITING
"OSPEDALE di LECCE VITO FAZZI", Lecce
NOT_YET_RECRUITING
Presidio Ospedaliero Unico Av3 - Ospedale Generale Provinciale - Macerata, Macerata
RECRUITING
Istituto Clinico Humanitas, Milan
NOT_YET_RECRUITING
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
NOT_YET_RECRUITING
Azienda Ospedaliero-Universitaria di Modena, Modena
NOT_YET_RECRUITING
Istituto Oncologico Veneto, Padua
RECRUITING
Azienda Ospedaliero-Universitaria di Parma, Parma
NOT_YET_RECRUITING
Istituti Clinici Scientifici Maugeri, Pavia
ACTIVE_NOT_RECRUITING
Irccs Istituto in Tecnologie Avanzate E Modelli Assistenziali in Oncologia Di Reggio Emilia, Reggio Emilia
NOT_YET_RECRUITING
Azienda Ospedaliera San Camillo-Forlanini, Roma
RECRUITING
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome
NOT_YET_RECRUITING
Azienda Ospedaliera Santa Maria Terni, Terni
ACTIVE_NOT_RECRUITING
Azienda Ospedaliero-Universitaria S. Luigi Gonzaga, Torino
ACTIVE_NOT_RECRUITING
Azienda Ospedaliero-Universitaria Integrata Verona - Borgo Roma, Verona
Collaborators (1)
Clinical Research Technology S.r.l.
INDUSTRY
Consorzio Oncotech
OTHER